Biological Intellectual Property Protection Act of 2025
Summary
HR6624 forces a structural onshoring of U.S. synthetic biology IP and manufacturing away from PRC entities. Domestic pure-plays Ginkgo Bioworks ($DNA) and Twist Bioscience ($TWST) are direct beneficiaries, while large biopharma Amgen ($AMGN) and Regeneron ($REGN) face near-term capex pressure but reduced long-term IP risk. The bill advanced out of committee with bipartisan support and has an identical Senate companion bill, increasing passage probability.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR6624 forces onshoring of synthetic biology IP and manufacturing away from PRC entities; no direct spending, but massive supply chain restructuring
- 2.Domestic pure-plays $DNA (Ginkgo Bioworks) and $TWST (Twist Bioscience) are direct structural beneficiaries
- 3.Large biopharma $AMGN and $REGN face near-term capex pressure but gain long-term IP protection; neutral with downside risk on execution
- 4.Bipartisan support and a Senate companion bill increase passage probability; floor vote likely within weeks
Market Implications
The bill is a catalyst for the U.S. synthetic biology sector. $DNA at $8.07 with a 30-day gain of 31.48% has already priced in partial expectation, but full passage could drive further multiple expansion as order volume from redirected biopharma spending materializes. $AMGN at $348.89 and $REGN at $706.58 are pricing in the capex headwind—watch for floor action as a binary event that could widen the spread between pure-plays and diversified biopharma. For retail investors, the clearest play is $DNA as a high-conviction beneficiary with direct revenue impact from onshoring orders.
Full Analysis
On April 22, 2026, the House Foreign Affairs Committee ordered HR6624, the Biological Intellectual Property Protection Act of 2025, reported out on a 30-14 vote. The bill, sponsored by Rep. Davidson (R-OH) with 11 cosponsors including both Republicans and Democrats, restricts export of U.S. synthetic biology intellectual property and sensitive information to PRC entities. It now awaits a floor vote in the House. An identical companion bill, S3452, has been introduced in the Senate, signaling bipartisan coalition building.
The bill is an authorization bill—it sets policy and trade restrictions but does not appropriate funding. The mechanism is an export control: it prohibits transfer of synthetic biology IP and sensitive data to PRC-linked entities. There is no direct government spending allocation; the economic impact comes from forced restructuring of private sector supply chains.
Structural winners are domestic synthetic biology pure-play companies. Ginkgo Bioworks ($DNA) at $8.07 has rallied 31.48% in the last 30 days, reflecting market anticipation of this shift. Twist Bioscience ($TWST), though not provided in the market data here, is similarly positioned as a U.S.-based DNA synthesis leader. Both companies gain strategic value as compliant domestic alternatives to PRC-based CDMOs.
Structural laggards are large biopharma companies with PRC-linked manufacturing or R&D partnerships. Amgen ($AMGN) at $348.89 (30-day -0.84%) and Regeneron ($REGN) at $706.58 (30-day -8.55%) face near-term capital expenditure pressure to onshore or nearshore production. However, both benefit from reduced IP theft risk and supply chain security long-term, which supports earnings stability.
Legislative timeline: the bill must pass the full House, then the Senate (where identical S3452 awaits committee action), then be signed by the President. Given bipartisan support and a committee vote with only 14 nays, passage probability is elevated but not guaranteed. Floor action could occur within weeks.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Some confirming evidence found across public data sources
What the bill does
Export restriction on U.S. synthetic biology IP and sensitive information to PRC entities; creates structural barrier to PRC-based CDMO partnerships
Who must act
U.S. biopharma companies and CDMOs currently sourcing synthetic biology services or transferring IP to PRC-linked entities
What happens
U.S. biopharma must onshore or nearshore synthetic biology R&D and production, increasing demand for domestic pure-play platform providers
Stock impact
Ginkgo Bioworks ($DNA) is a U.S.-based synthetic biology pure-play with cell programming platform revenue; immediate strategic value as a compliant, domestic alternative to PRC-based CDMOs. 30-day +31.48% price momentum reflects market pricing in this demand shift.
What the bill does
Export restriction on U.S. synthetic biology IP and sensitive information to PRC entities; restricts DNA synthesis and gene-editing service transfers
Who must act
U.S. biopharma and research institutions using PRC-based gene synthesis or DNA manufacturing services
What happens
Shift of DNA synthesis orders to U.S.-based providers, increasing domestic order volume and pricing power
Stock impact
Twist Bioscience ($TWST) is a U.S. pure-play DNA synthesis provider with Silicon Valley manufacturing; directly captures orders redirected from PRC competitors. Not provided in real market data, but structurally positioned as beneficiary.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
To amend title XVIII of the Social Security Act to ensure equitable payment for, and preserve Medicare beneficiary access to, cancer treatments under the Medicare hospital outpatient prospective payment system.
To authorize the Secretary of Defense to carry out a program to support the defense biotechnology supply chain, and for other purposes.
Skinny Labels, Big Savings Act
Small Biotech Innovation Act
Elijah E. Cummings Family Asthma Act
Protecting Americans from Unsafe Drugs Act of 2026
ABC Safe Drug Act
DELL FEDERAL SYSTEMS L.P: $1.0B Department of Veterans Affairs Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
National Security Presidential Memorandum/NSPM-12
This memorandum rescinds previous national security directives and re-establishes the Committee on National Security Systems (CNSS) to enforce baseline cybersecurity standards across all National Security Systems (NSS) operated by the Department of War, Intelligence Community, and Federal Civilian Executive Branch agencies. It creates binding directives and complementary standards that must meet or exceed NIST guidelines, empowers the NSA Director as the National Manager to issue emergency directives and cryptography requirements, and holds agency heads accountable through government-wide oversight.
National Security Presidential Memorandum/NSPM-11
This memorandum directs the national security enterprise (including the Department of War, intelligence agencies, and others) to accelerate the adoption, adaptation, and assurance of AI technologies for military and intelligence missions. It mandates updates to DOD Directive 3000.09 on autonomous weapons within 90 days, requires termination of contracts with companies that repeatedly violate policy (e.g., by enabling adversary control or embedding bias), and emphasizes supply chain resilience and multi-vendor sourcing to avoid single-vendor dependencies.
Strengthening Customs Enforcement
This executive order directs the Secretary of Homeland Security to revise customs enforcement regulations within 180 days, requiring importers of record (IORs) to maintain minimum tangible domestic assets or bonding, disclose ownership and business affiliations, and maintain good standing with CBP. It prohibits foreign IORs from filing informal entries for low-value articles and imposes additional bonding and CTPAT validation requirements for foreign IORs on formal entries, aiming to enhance compliance and revenue collection.